Recent studies suggest that chronic inflammation contributes to epithelial–mesenchymal transition (EMT), resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), and metastatic potential in EGFR-mutant NSCLC (16). This evidence concerns the gene EGFR and non-small cell lung carcinoma.